BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

540 related articles for article (PubMed ID: 35645140)

  • 1. Transient elastography for the prevalence of non-alcoholic fatty liver disease in patients with type 2 diabetes: Evidence from the CORDIAL cohort study.
    Alfadda AA; Sherbeeni SM; Alqutub AN; Aldosary AS; Aldaghri NM; Taylor-Robinson SD; Alqahtani SA; Gul R; Almaghamsi AM
    Saudi J Gastroenterol; 2022; 28(6):426-433. PubMed ID: 35645140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening for hepatic fibrosis and steatosis in Turkish patients with type 2 diabetes mellitus: A transient elastography study.
    Demir M; Deyneli O; Yılmaz Y
    Turk J Gastroenterol; 2019 Mar; 30(3):266-270. PubMed ID: 30411703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography.
    Lai LL; Wan Yusoff WNI; Vethakkan SR; Nik Mustapha NR; Mahadeva S; Chan WK
    J Gastroenterol Hepatol; 2019 Aug; 34(8):1396-1403. PubMed ID: 30551263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of steatosis and fibrosis in young adults in the UK: a population-based study.
    Abeysekera KWM; Fernandes GS; Hammerton G; Portal AJ; Gordon FH; Heron J; Hickman M
    Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):295-305. PubMed ID: 31954687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatic Steatosis and Fibrosis in Type 2 Diabetes: A Risk-Based Approach to Targeted Screening.
    Poustchi H; Alaei-Shahmiri F; Aghili R; Nobarani S; Malek M; Khamseh ME
    Arch Iran Med; 2021 Mar; 24(3):177-186. PubMed ID: 33878875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening for nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography - a prospective, cross sectional study.
    Mikolasevic I; Domislovic V; Turk Wensveen T; Delija B; Klapan M; Juric T; Lukic A; Mijic A; Skenderevic N; Puz P; Ostojic A; Krznaric Z; Radic-Kristo D; Filipec Kanizaj T; Stimac D
    Eur J Intern Med; 2020 Dec; 82():68-75. PubMed ID: 32839076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Visceral Adipose Tissue and Non-alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes.
    Nobarani S; Alaei-Shahmiri F; Aghili R; Malek M; Poustchi H; Lahouti M; Khamseh ME
    Dig Dis Sci; 2022 Apr; 67(4):1389-1398. PubMed ID: 33788095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transient elastography and controlled attenuation parameter to evaluate hepatic steatosis and liver stiffness in postpartum patients.
    Hussain FN; Rosenbluth E; Feldman KM; Strauss TS; Schneider E; Schmidt-Beauchat E; Rodriguez-Rivas C; Brustman L; Kushner T
    J Matern Fetal Neonatal Med; 2023 Dec; 36(1):2190838. PubMed ID: 36935368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High Prevalence of Advanced Liver Fibrosis Assessed by Transient Elastography Among U.S. Adults With Type 2 Diabetes.
    Ciardullo S; Monti T; Perseghin G
    Diabetes Care; 2021 Feb; 44(2):519-525. PubMed ID: 33303638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and risk factors of nonalcoholic steatohepatitis with significant fibrosis in people with HIV.
    Michel M; Labenz C; Wahl A; Anders M; Armandi A; Huber Y; Galle PR; Sprinzl M; Schattenberg JM
    AIDS; 2022 Oct; 36(12):1665-1674. PubMed ID: 35849074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum levels of soluble dipeptidyl peptidase-4 in type 2 diabetes are associated with severity of liver fibrosis evaluated by transient elastography (FibroScan) and the FAST (FibroScan-AST) score, a novel index of non-alcoholic steatohepatitis with significant fibrosis.
    Sagara M; Iijima T; Kase M; Kato K; Sakurai S; Tomaru T; Jojima T; Usui I; Aso Y
    J Diabetes Complications; 2021 May; 35(5):107885. PubMed ID: 33602617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical spectrum of non-alcoholic fatty liver disease in patients with diabetes mellitus.
    Chen K; Sng WK; Quah JH; Liu J; Chong BY; Lee HK; Wang XF; Tan NC; Chang PE; Tan HC; Bee YM; Goh GBB
    PLoS One; 2020; 15(8):e0236977. PubMed ID: 32822391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic impact of liver fibrosis and steatosis by transient elastography for cardiovascular and mortality outcomes in individuals with nonalcoholic fatty liver disease and type 2 diabetes: the Rio de Janeiro Cohort Study.
    Cardoso CRL; Villela-Nogueira CA; Leite NC; Salles GF
    Cardiovasc Diabetol; 2021 Sep; 20(1):193. PubMed ID: 34560854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening.
    Lomonaco R; Godinez Leiva E; Bril F; Shrestha S; Mansour L; Budd J; Portillo Romero J; Schmidt S; Chang KL; Samraj G; Malaty J; Huber K; Bedossa P; Kalavalapalli S; Marte J; Barb D; Poulton D; Fanous N; Cusi K
    Diabetes Care; 2021 Feb; 44(2):399-406. PubMed ID: 33355256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
    Eddowes PJ; Sasso M; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Guha IN; Cobbold JF; Deeks JJ; Paradis V; Bedossa P; Newsome PN
    Gastroenterology; 2019 May; 156(6):1717-1730. PubMed ID: 30689971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease.
    Shimizu M; Suzuki K; Kato K; Jojima T; Iijima T; Murohisa T; Iijima M; Takekawa H; Usui I; Hiraishi H; Aso Y
    Diabetes Obes Metab; 2019 Feb; 21(2):285-292. PubMed ID: 30178600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased frequency of hepatic steatosis and fibrosis in patients with gout detected by transient elastography.
    Schlesinger N; Patel A; Rustgi VK; Yeo AE; Lipsky PE
    Clin Exp Rheumatol; 2024 Jan; 42(1):86-91. PubMed ID: 37497724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-alcoholic fatty liver disease (NAFLD) and significant hepatic fibrosis defined by non-invasive assessment in patients with type 2 diabetes.
    Sobhonslidsuk A; Pulsombat A; Kaewdoung P; Petraksa S
    Asian Pac J Cancer Prev; 2015; 16(5):1789-94. PubMed ID: 25773826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of controlled attenuation parameter and liver stiffness measurement for detecting increased arterial stiffness in asymptomatic populations in China.
    Yu XY; Song XX; Tong YL; Wu LY; Song ZY
    Medicine (Baltimore); 2020 Nov; 99(48):e23360. PubMed ID: 33235107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients.
    Garg H; Aggarwal S; Shalimar ; Yadav R; Datta Gupta S; Agarwal L; Agarwal S
    Surg Obes Relat Dis; 2018 Jan; 14(1):81-91. PubMed ID: 29126863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.